SKP2-mediated degradation of p27 has been regarded as an oncogenic driver [208] and the SKP2-PTEN axis is implicated in breast cancer, lung cancer, prostate cancer, colorectal cancer, gastric cancer, and prostate cancer [209]. Here, SKP2 is linked to prostate cancer.